Generic medicine

Atezolizumab: Brands, Price & Uses in Bangladesh

Established (FDA-Approved) Indications Atezolizumab is a PD-L1 immune checkpoint inhibitor approved, alone or in combination with other anticancer agents and more.

Forms:IV Infusion

About Atezolizumab

Indications of Atezolizumab

Established (FDA-Approved) Indications

Atezolizumab is a PD-L1 immune checkpoint inhibitor approved, alone or in combination with other anticancer agents, for the treatment of several malignancies under oncology specialist supervision:

  • Non-small cell lung cancer (NSCLC): Metastatic NSCLC in combination with bevacizumab, paclitaxel, and carboplatin; metastatic non-squamous NSCLC in combination with nab-paclitaxel and carboplatin; metastatic NSCLC as a single agent following prior platinum-based chemotherapy or in first-line for tumors with high PD-L1 expression; adjuvant treatment after resection and platinum-based chemotherapy in stage II to IIIA NSCLC with PD-L1 expression on ≥1% of tumor cells.
  • Small cell lung cancer (SCLC): First-line treatment of extensive-stage SCLC in combination with carboplatin and etoposide.
  • Hepatocellular carcinoma (HCC): Unresectable or metastatic HCC in patients who have not received prior systemic therapy, in combination with bevacizumab.
  • Melanoma: BRAF V600 mutation-positive unresectable or metastatic melanoma, in combination with cobimetinib and vemurafenib.
  • Alveolar soft part sarcoma (ASPS): Unresectable or metastatic ASPS in adult and pediatric patients 2 years of age and older (approved under accelerated approval based on tumor response rate).

Note: Some earlier accelerated-approval indications of Atezolizumab in urothelial carcinoma have since been withdrawn in certain markets following confirmatory trial results; use in that setting should follow current local regulatory and oncology guideline status.

All uses of Atezolizumab require confirmation of diagnosis, staging, and (where specified) biomarker (PD-L1) testing, and must be initiated and monitored by a qualified oncology specialist.

Dosage & Administration of Atezolizumab

Dosing by Indication (Adult)

IndicationRecommended DoseFrequency
NSCLC / SCLC / HCC / Melanoma (adult, most regimens)1200 mg IVEvery 3 weeks
Alternative dosing (select regimens)1680 mg IVEvery 4 weeks
Alternative dosing (select regimens)840 mg IVEvery 2 weeks

The specific dose and schedule of Atezolizumab depend on the cancer type, disease stage, and the combination regimen being used, and must be individualized by the treating oncologist.

Administration

Atezolizumab must be diluted in 0.9% Sodium Chloride Injection before use and administered as an intravenous infusion only — never as an intravenous push or bolus. The first infusion is given over 60 minutes; if well tolerated, subsequent infusions may be given over 30 minutes. Atezolizumab should not be mixed with, or administered as an infusion with, other medicinal products, and should be given through a dedicated line.

Patients should be monitored during and for at least the first hour after infusion for signs of infusion-related reactions.

Side Effects of Atezolizumab

Common Side Effects

  • Fatigue and asthenia
  • Nausea and decreased appetite
  • Cough and dyspnea
  • Diarrhea
  • Musculoskeletal pain
  • Fever (pyrexia)
  • Rash and pruritus
  • Infection

Serious Side Effects

See Precautions and Warnings for full detail on immune-mediated adverse reactions (pneumonitis, hepatitis, colitis, endocrinopathies, nephritis, skin reactions, and others) and infusion-related reactions associated with Atezolizumab.

Contraindications of Atezolizumab

Atezolizumab is contraindicated in patients with a known severe hypersensitivity reaction to Atezolizumab or to any of its excipients.

Frequently Asked Questions about Atezolizumab

What is Atezolizumab used for?

Atezolizumab is a cancer immunotherapy medicine (a PD-L1 checkpoint inhibitor) used, alone or with other anticancer drugs, to treat certain lung cancers, liver cancer, melanoma, and alveolar soft part sarcoma, as prescribed by an oncologist.

How is Atezolizumab given?

Atezolizumab is given only as a slow intravenous (IV) infusion in a hospital or cancer treatment center, typically every 2 to 4 weeks depending on the regimen; it is never taken by mouth or injected at home.

What are the most serious side effects of Atezolizumab?

Atezolizumab can cause the immune system to attack healthy organs, leading to inflammation of the lungs, liver, bowel, hormone glands, kidneys, or skin. Symptoms such as new cough or breathlessness, severe diarrhea, yellowing of the skin/eyes, unusual fatigue, or rash should be reported to your oncology team immediately, as these may need treatment with corticosteroids or a pause in therapy.

Can Atezolizumab be used during pregnancy?

Atezolizumab may harm an unborn baby, so it should be used in pregnancy only if the benefit clearly outweighs the risk and under close physician supervision. Women who could become pregnant should use effective contraception during treatment with Atezolizumab and for at least 5 months after the last dose.

Is Atezolizumab safe while breastfeeding?

It is not known if Atezolizumab passes into breast milk. Because of possible harm to a nursing infant, breastfeeding is generally not recommended during treatment with Atezolizumab and for at least 5 months after the last dose; discuss feeding options with your physician.

What should I tell my doctor before starting Atezolizumab?

Tell your doctor if you have an autoimmune disease, have had an organ transplant, are pregnant or breastfeeding, or have had a prior reaction to another immunotherapy, before starting Atezolizumab, as these may affect whether and how it is used.

Disclaimer

The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.

DoctorBlogArticles